Glaucoma is a group of eye diseases which result in damage to the optic nerve and cause vision loss.
The increasing demand for combination drugs will be one of the primary drivers of the open-angle glaucoma therapeutics market. Combination drugs have minimal adverse effects and help in overcoming the limitations of monotherapy. Combination drugs also help in improving tolerability by allowing the use of the two compounds below their dose thresholds.

Market Analysis and Insights: Global Open-Angle Glaucoma Therapeutics Market
The global Open-Angle Glaucoma Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Open-Angle Glaucoma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Open-Angle Glaucoma Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Open-Angle Glaucoma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Open-Angle Glaucoma Therapeutics market.

Global Open-Angle Glaucoma Therapeutics Scope and Market Size
Open-Angle Glaucoma Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Open-Angle Glaucoma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Prostaglandin Analogs (PGAs)
Combination of PGAs
Other

Segment by Application
Hospital
Clinic
Research Institute
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Aerie Pharmaceuticals Inc.
Allergan Plc
Bausch Health Companies, Inc.
Novartis AG
Pfizer Inc.